Cinnarizine 25 mg.
blocker of "slow" calcium channels.
Selective BMCC reduces the Ca2 + entry into cells and reduces their concentration in the plasma membrane depot, reduces the tone of the smooth muscles of arterioles, and enhances the vasodilating effect of carbon dioxide.
Directly affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially in relation to cerebral vessels), without having a significant effect on blood pressure.
It exhibits moderate antihistamine activity, reduces the excitability of the vestibular apparatus, and lowers the tone of the sympathetic nervous system.
It is effective in patients with latent insufficiency of cerebral circulation, initial atherosclerosis of the brain vessels and chronic diseases of the brain vessels with post-stroke focal symptoms.
In patients with impaired peripheral circulation improves blood supply to organs and tissues (including the myocardium), enhances postischemic vasodilation.
Increases the elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity. Increases muscle resistance to hypoxia.
TCmax after oral administration - 1-3 hours, communication with plasma proteins - 91%.
It is completely metabolized in the liver (via dealkylation). T1 / 2 - 4 hours.
It is excreted in the form of metabolites: 1/3 - by the kidneys and 2/3 - with feces.
Chronic cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration).
Vestibular disorders (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinth origin).
Prevention of kinetoses ("road sickness" - sea and air sickness).
Migraine (seizure prevention).
Peripheral circulatory disorders (intermittent claudication, Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders, including trophic and varicose ulcers).
Hypersensitivity, pregnancy, lactation, children under 5 years old.
Carefully. For Lactose-containing drugs (optional): lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
From the nervous system: drowsiness, increased fatigue, headache, extrapyramidal disorders (tremor of the extremities and increased muscle tone, hypokinesia), depression.
From the digestive system: dry oral mucosa, epigastric pain, dyspepsia, cholestatic jaundice.
From the skin: increased sweating, lichen planus (extremely rare).
Allergic reactions: skin rash.
Other: decreased blood pressure, weight gain, lupus-like syndrome.
Enhances the action of ethanol, sedative drugs, tricyclic antidepressants.
How to take, course of administration and dosage
Inside, after a meal.
In chronic cerebrovascular insufficiency - 25 mg 3 times a day, in drops - 8 drops 3 times a day or 1 capsule (75 mg) once a day.
In case of a violation of peripheral circulation - 50-75 mg 3 times a day.
For the prevention of sea and air sickness - 25 mg 30 minutes before the upcoming trip, if necessary, the dose is repeated after 6 hours; for children from 5 years - 1/2 dose for adults.
With vestibular disorders - 25 mg 3 times a day. For children, the dose is reduced by 2 times.
The maximum daily dose should not exceed 225 mg. With high sensitivity to the drug, treatment begins with 1/2 dose, increasing it gradually.
To achieve the optimal therapeutic effect, the drug should be taken continuously, for a long time - from several weeks to several months.
Symptoms: vomiting, drowsiness, tremor, excessive decrease in blood pressure, coma.
Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.
Due to the antihistamine effect, cinnarizine can affect the result during the anti-doping control of athletes (false-positive result), as well as neutralize positive reactions during skin diagnostic tests (treatment should be canceled 4 days before the study).
With prolonged use, a follow-up examination of the liver, kidneys, and peripheral blood picture is recommended.
Women taking cinnarizine are not recommended to breastfeed.
Patients with Parkinson's disease should be prescribed only in cases where the benefits of its appointment exceed the possible risk of worsening.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.